DK0697111T3 - Celle-afprøvning for Alzheimers sygdom - Google Patents

Celle-afprøvning for Alzheimers sygdom

Info

Publication number
DK0697111T3
DK0697111T3 DK94915953.7T DK94915953T DK0697111T3 DK 0697111 T3 DK0697111 T3 DK 0697111T3 DK 94915953 T DK94915953 T DK 94915953T DK 0697111 T3 DK0697111 T3 DK 0697111T3
Authority
DK
Denmark
Prior art keywords
alzheimer
disease
cell testing
cells
intracellular calcium
Prior art date
Application number
DK94915953.7T
Other languages
Danish (da)
English (en)
Inventor
Daniel L Alkon
Rene Etcheberrigaray
Ito Etsuro
Gary E Gibson
Original Assignee
Cornell Res Foundation Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc, Us Health filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of DK0697111T3 publication Critical patent/DK0697111T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94915953.7T 1993-05-03 1994-05-02 Celle-afprøvning for Alzheimers sygdom DK0697111T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/056,456 US5580748A (en) 1993-05-03 1993-05-03 Diagnostic tests for alzheimers disease

Publications (1)

Publication Number Publication Date
DK0697111T3 true DK0697111T3 (da) 1998-03-02

Family

ID=22004526

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94915953.7T DK0697111T3 (da) 1993-05-03 1994-05-02 Celle-afprøvning for Alzheimers sygdom

Country Status (12)

Country Link
US (1) US5580748A (de)
EP (1) EP0697111B1 (de)
JP (1) JPH09500202A (de)
AT (1) ATE155888T1 (de)
AU (1) AU689776B2 (de)
CA (1) CA2162048A1 (de)
DE (1) DE69404460T2 (de)
DK (1) DK0697111T3 (de)
ES (1) ES2108455T3 (de)
GR (1) GR3025126T3 (de)
HK (1) HK1001500A1 (de)
WO (1) WO1994025872A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US6300085B1 (en) 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
US5902732A (en) * 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
US6573063B2 (en) * 1995-10-04 2003-06-03 Cytoscan Sciences, Llc Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
US6183975B1 (en) * 1997-02-24 2001-02-06 J. Jay Gargus Method of detection of congenital disease
JP2001523002A (ja) * 1997-11-10 2001-11-20 ブリストル−マイヤーズ スクイブ カンパニー アルツハイマー病の診断方法
US6087118A (en) * 1999-03-04 2000-07-11 Bristol-Myers Squibb Company Method for diagnosing alzheimer's disease
CA2377382A1 (en) * 1999-07-01 2001-01-11 Scios, Inc. Prevention and treatment of amyloid-associated disorders
WO2001077686A2 (en) * 2000-04-05 2001-10-18 Neurologic, Inc. Cellular calcium responce for diagnosis of alzheimer's disease
US6495335B2 (en) * 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
GB0107231D0 (en) 2001-03-22 2001-05-16 Imp College Innovations Ltd Patch clamp
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US20070054890A1 (en) 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
CN101300489A (zh) * 2005-11-03 2008-11-05 红点生物公司 Trpm5离子通道的高通量筛选实验
US20080025961A1 (en) 2006-07-28 2008-01-31 Alkon Daniel L Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory
EP3332797A3 (de) * 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Therapeutische wirkungen von bryostatinen, bryologen und anderen damit zusammenhängenden substanzen auf durch kopftraumata herbeigeführte gedächtnisstörungen und hirnverletzungen
CL2007002908A1 (es) * 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
EP2483684B1 (de) * 2009-10-02 2018-04-18 Blanchette Rockefeller Neurosciences, Institute Fibroblast wachstumsmuster zur diagnose der alzheimer-krankheit
US20160186263A1 (en) 2013-05-09 2016-06-30 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
WO2015089375A1 (en) 2013-12-13 2015-06-18 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
JPH03505868A (ja) * 1988-04-08 1991-12-19 マサチユセツツ・インスチチユート・オブ・テクノロジー 神経性疾患を治療するための方法及び組成物

Also Published As

Publication number Publication date
GR3025126T3 (en) 1998-02-27
WO1994025872A1 (en) 1994-11-10
AU6778494A (en) 1994-11-21
CA2162048A1 (en) 1994-11-10
DE69404460T2 (de) 1998-02-26
AU689776B2 (en) 1998-04-09
EP0697111A1 (de) 1996-02-21
JPH09500202A (ja) 1997-01-07
ES2108455T3 (es) 1997-12-16
ATE155888T1 (de) 1997-08-15
EP0697111B1 (de) 1997-07-23
DE69404460D1 (de) 1997-09-04
US5580748A (en) 1996-12-03
HK1001500A1 (en) 1998-06-19

Similar Documents

Publication Publication Date Title
DK0697111T3 (da) Celle-afprøvning for Alzheimers sygdom
DE69529992D1 (de) Cell test und diagnostischer kit für alzheimer-erkrankung
WO1999058981A3 (en) Diagnostic tests for alzheimer's disease
ATE155811T1 (de) Menschliche cyclooxygenase-2cdna und bestimmung von menschliche cyclooxygenase-2-inhibierung
WO2000066762A3 (en) Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
DE60027762D1 (de) Diagnose und behandlung von arthritischen erkrankungen
ATE228822T1 (de) Mikroemulsionen zur verwendung als träger zur verabreichung von wirkstoffen
ATE188036T1 (de) Glykoalkaloide
EP0982988A4 (de) Im wesentlichen reines zonulin als physiologischer modulator von "tight junctions" bei säugern
DE69430951D1 (de) Zusammensetzung enthaltend bradykinin zum selektiven offnen von anormalen gehirngewebes kapillaren
ES467222A1 (es) Procedimiento de preparacion de una emulsion del tipo agua en aceite o aceite en agua estable.
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
FI870818A7 (fi) Ihmisen normaaleista paksusuolen soluista saatu kudosplasminogeeni-aktivaattori.
ATE207295T1 (de) Fungizide mischungen
Seller et al. Magnesium metabolism in hypertension
NO986218L (no) FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
ES8707565A1 (es) Un procedimiento para producir un anticuerpo monoclonal
ATE412435T1 (de) Verwendung eines färbemittels zur anfärbung von der augenlinsenkapsel oder von an der netzhaut des auges entstandenen membranen
ATE168005T1 (de) Verwendung von procystein als depigmentierendes mittel
AU5336796A (en) Method for detecting allergy
EA199600113A2 (ru) Способ подбора индивидуальных параметров гипероксического воздействия
Holland et al. Cytochemically Detectable Glucose-6-Phosphate Denydrogenase-Stimulating/Na-KATPase-Inhibiting Activity of Plasma and Hypothalamus in Reduced Renal Mass Hypertension
WO1996031621A3 (en) Method for determining the responsiveness of individuals to 5-ht2 receptor modulating agents